{"id":2690,"date":"2019-10-01T12:02:00","date_gmt":"2019-10-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/neue-europaeische-leitlinie-zur-lipidsenkung-as-low-as-possible"},"modified":"2022-03-17T14:14:00","modified_gmt":"2022-03-17T13:14:00","slug":"neue-europaeische-leitlinie-zur-lipidsenkung-as-low-as-possible","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/neue-europaeische-leitlinie-zur-lipidsenkung-as-low-as-possible","title":{"rendered":"Neue europ\u00e4ische &#8222;Leitlinie&#8220; zur Lipidsenkung: As low as possible?"},"content":{"rendered":"<p>Zusammenfassung: Die neuen Leitlinien der European Society of Cardiology (ESC) und der European Atherosclerosis Society (EAS) erweitern erheblich den Kreis der medikament\u00f6s behandlungsbed\u00fcrftigen Menschen mit Hyperlipid\u00e4mien. Die Grenze zwischen Prim\u00e4r- und Sekund\u00e4rpr\u00e4vention wird aufgehoben, und die LDL-Zielwerte werden nochmals stark herabgesetzt. Ezetimib und PCSK9-Hemmer erhalten eine Klasse-1-Empfehlung, ohne dass es neue und stichhaltige Belege f\u00fcr [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die neuen Leitlinien der European Society of Cardiology (ESC) und der European Atherosclerosis Society (EAS) erweitern erheblich den Kreis der medikament\u00f6s behandlungsbed\u00fcrftigen Menschen mit Hyperlipid\u00e4mien. Die Grenze zwischen Prim\u00e4r- und Sekund\u00e4rpr\u00e4vention wird aufgehoben, und die LDL-Zielwerte werden nochmals stark herabgesetzt. Ezetimib und PCSK9-Hemmer erhalten eine Klasse-1-Empfehlung, ohne dass es neue und stichhaltige Belege f\u00fcr [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,1518,495,1272,1046,1274,451,452,449,3065,2879,1166,71,455,453,498,456,454,65,1525,1526,1522,801,1043,505,443],"class_list":["post-2690","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-alirocumab","tag-angina-pectoris","tag-arteriosklerose","tag-atorvastatin","tag-cholesterin","tag-cholesterinsynthese-hemmer","tag-cholestyramin","tag-cse-hemmer","tag-evolocumab","tag-ezetimib","tag-fluvastatin","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-myokardinfarkt","tag-pcsk9","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-pravastatin","tag-rosuvastatin","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2690"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2690\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}